NEW YORK (360Dx) – Itus said today it has renewed a collaborative agreement with the Wistar Institute for the development of its Cchek early cancer detection technology.

Itus is developing the Cchek platform through Anixa Diagnostics, its subsidiary. The platform is a series of non-invasive blood tests for the early detection of solid tumor cancers based on the body's immunological response to malignancy.

Itus Chairman and CEO Amit Kumar said in a statement, "Wistar's R&D support has been and continues to be valuable to the development of Cchek."